Emerging retatrutide, a dual -action treatment targeting simultaneously GLP-1 and GIP receptors, is sparking considerable interest within the healthcare community. Initial clinical research have revealed impressive decreases in physical size and gains in physiological markers for people with overweight. Scientists believe this unique approach could